Answers are grounded in this paper and cite their sources.
Cardiovascular mortality rate is increasing all over the world. One of the most important aetiological factors of the lethal outcome is diabetes mellitus. Medicines that can be used for treating this disease include agents which increase insulin secretion (insulin secretagogues), enhance the effect of insulin (insulin sensitizers), or inhibit glucose absorption. All these can be used as monotherapy and in various combinations as well. In the practice, the combination of rosiglitazone and glimepiride seems to be very useful. As each component exerts its activity on different target points, they complement each other well. Glimepiride stimulates insulin secretion in the beta cells, and leads to a reduction of blood glucose levels, while rosiglitazone stimulates peroxisome proliferators-activated receptor-gamma and improves insulin resistance at the vascular and metabolically active cells. The combination of glimepiride and rosiglitazone is usually well tolerated by the patients, and the fix combination also...
No takes yet. Share an insight, caveat, or question.
Fehér et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: